Holen Sie sich die Stockscreener-App
10.72
33.67%
2.70
Vorhandelsmarkt:
10.65
-0.07
-0.65%
Nutriband Inc Aktie (NTRB) Neueste Nachrichten
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-Up for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch - MarketScreener
Nutriband and Kindeva Complete Commercial Manufacturing - GlobeNewswire
Nutriband and Kindeva Complete Commercial Manufacturing Process - GuruFocus
Nutriband (NTRB) Advances Aversa Fentanyl Manufacturing Process | NTRB Stock News - GuruFocus
Nutriband, Kindeva complete commercial manufacturing process scale-up for Aversa - TipRanks
Revolutionary Abuse-Deterrent Fentanyl Patch Completes Manufacturing Scale-up: $200M Market Potential - Stock Titan
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development - citybuzz -
(NTRB) Proactive Strategies - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology - The Globe and Mail
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology - citybuzz -
Nutriband secures US patent for abuse deterrent patch technology By Investing.com - Investing.com South Africa
Nutriband issued U.S. patent for transdermal abuse deterrent technology - TipRanks
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology - The Manila Times
Nutriband secures US patent for abuse deterrent patch technology - Investing.com Australia
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband (NTRB) Secures Patent for Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband Secures Game-Changing Patent for First-Ever Abuse-Deterrent Fentanyl Patch Technology - Stock Titan
Nutriband (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology - Barchart.com
Nutriband (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value - The Globe and Mail
Nutriband Inc. Pioneers Abuse-Deterrent Technology with AVERSA, Targets $800 Million Market Potential - citybuzz -
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference - GlobeNewswire
Nutriband (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference - The Globe and Mail
Nutriband CEO Reveals Growth Strategy: Exclusive Virtual Presentation at Noble Capital Conference - Stock Titan
Nutriband reports Q1 revenue up 63% y/y at $667K - TipRanks
Nutriband First Quarter 2026 Earnings: EPS Beats Expectations - Yahoo Finance
Nutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development - The Globe and Mail
Nutriband Inc. Reports Revenue Results for the First Quarter Ended April 30, 2025 - MarketScreener
Nutriband Inc. Provides Update on the Development of AVERSA Fentanyl - MarketScreener
Nutriband (NTRB) Expands Kinesiology Tape Production and Advances Drug Delivery Solutions | NTRB Stock News - GuruFocus
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - The Manila Times
Nutriband Inc. Quarterly Report Highlights Record Revenue - GlobeNewswire
Nutriband Q1 Revenue Surges 63% as AVERSA Fentanyl Development Advances | NTRBW Stock News - Stock Titan
Nutriband Inc. (NTRB) reports Q1 loss, misses revenue estimates - FXStreet
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates - MSN
NutriBand Inc. SEC 10-Q Report - TradingView
(NTRB) Investment Analysis - news.stocktradersdaily.com
Nutriband Addresses Opioid Pain Management Challenges with Innovative Transdermal Solution - citybuzz -
Nutriband (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode Of The Biomedwire Podcast Featuring Gareth Sheridan, CEO Of Nutriband Inc. - marketscreener.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc. - GlobeNewswire
Nutriband (NASDAQ: NTRB) Charts Path To Commercialization - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Nutriband Advances Opioid Pain Patch Technology with Strategic Partnership - citybuzz -
Concern Rises over Market Valutions and Structural Vibrations - The Globe and Mail
(NTRB) On The My Stocks Page - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances - Barchart.com
Nutriband Expands Market Presence Through Strategic Health Industry Partnerships - citybuzz -
Why Isn't Palantir's Stock Taking Off After Another Strong Quarter? - The Globe and Mail
Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch - Barchart.com
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis Regulatory Changes - citybuzz -
Nutriband (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape - Barchart.com
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 - ACCESS Newswire
(NTRB) Trading Report - news.stocktradersdaily.com
Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021 - ACCESS Newswire
Nutriband (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting Milestones, Commercialization Goals - Barchart.com
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):